Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3270299 | 0.98 | PPARD (0.53) | PPARDPKMPPARAPTGDR2GPR139 | |
| SCHEMBL3276165 | 0.98 | PPARD (0.53) | PPARDPKMPPARAPTGDR2GPR139 | |
| SCHEMBL3275203 | 0.90 | PPARD (0.57) | PPARDPKMPPARAPTGDR2MRGPRX4 | |
| SCHEMBL3269565 | 0.90 | PPARD (0.57) | PPARDPKMPPARAPTGDR2MRGPRX4 | |
| SCHEMBL3275564 | 0.89 | PPARD (0.60) | PPARDPKMPPARA | |
| SCHEMBL3269950 | 0.89 | PPARD (0.48) | PPARDPPARAPTGDR2GPR139MRGPRX4 | |
| SCHEMBL3269059 | 0.89 | PPARD (0.63) | PPARDPPARAPTGDR2MRGPRX4 | |
| SCHEMBL3269288 | 0.89 | PPARD (0.63) | PPARDPPARA | |
| SCHEMBL3270672 | 0.87 | PPARD (0.58) | PPARDPKMPPARA | |
| SCHEMBL3280615 | 0.87 | PPARD (0.46) | PPARDGPR139MRGPRX4KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | claimed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | claimed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | claimed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| EP-1558572-B1 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PKM 697/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.